A5085863516- Multiple Myeloma Research and Treatments
- Protein Degradation and Inhibitors
- MicroRNA in disease regulation
- Histone Deacetylase Inhibitors Research
- Chemokine receptors and signaling
- Extracellular vesicles in disease
- Peptidase Inhibition and Analysis
- Vasculitis and related conditions
- CAR-T cell therapy research
- Nanoparticle-Based Drug Delivery
- Cancer Mechanisms and Therapy
- RNA Interference and Gene Delivery
- Atherosclerosis and Cardiovascular Diseases
- Mast cells and histamine
- Fibroblast Growth Factor Research
- Atrial Fibrillation Management and Outcomes
- Autophagy in Disease and Therapy
- Immunodeficiency and Autoimmune Disorders
- Chronic Lymphocytic Leukemia Research
- Biomarkers in Disease Mechanisms
- Adipose Tissue and Metabolism
- Liver physiology and pathology
- Cancer, Hypoxia, and Metabolism
- Ubiquitin and proteasome pathways
- Cell Adhesion Molecules Research
University of Bari Aldo Moro
2016-2025
Polyclinic General Hospital
2025
Polyclinic Medical Center
2025
Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari
2018-2020
Abstract Aberrant microRNA (miR) expression has an important role in tumour progression, but its involvement bone marrow fibroblasts of multiple myeloma patients remains undefined. We demonstrate that a specific miR profile parallels the transition from monoclonal gammopathy undetermined significance (MGUS) to myeloma. Overexpression miR‐27b‐3p and miR‐214‐3p triggers proliferation apoptosis resistance via FBXW7 PTEN/AKT/GSK3 pathways, respectively. Transient transfection inhibitors...
Cell adhesion in the multiple myeloma (MM) microenvironment has been recognized as a major mechanism of MM cell survival and development drug resistance. Here we addressed hypothesis that protein junctional molecule-A (JAM-A) may represent novel target clinical biomarker MM. We evaluated JAM-A expression lines 147 patient bone marrow aspirates biopsies at different disease stages. Elevated levels patient-derived plasma cells were correlated with poor prognosis. Moreover, circulating soluble...
The mammalian Target of Rapamycin (mTOR) is an intracellular serine/threonine kinase that mediates metabolism, cell survival and actin rearrangement. mTOR made two independent complexes, mTORC1 mTORC2, activated by the scaffold proteins RAPTOR RICTOR, respectively. activation triggers protein synthesis autophagy inhibition, while mTORC2 promotes progression, survival, reorganization, drug resistance through AKT hyper-phosphorylation on Ser473. Due to pivotal role in tumor cells, we evaluated...
Abstract Multiple myeloma, the second most common hematologic malignancy, frequently relapses because of chemotherapeutic resistance. Fibroblast growth factors (FGF) act as proangiogenic and mitogenic cytokines in multiple myeloma. Here, we demonstrate that autocrine FGF/FGFR axis is essential for myeloma cell survival progression by protecting cells from oxidative stress–induced apoptosis. In keeping with hypothesis intracellular redox status can be a target cancer therapy, blockade FGF...
The investigational drug MP0250 is a multi-specific DARPin® molecule that simultaneously binds and neutralizes VEGF HGF with high specificity affinity. Here we studied the antiangiogenic effects of in multiple myeloma (MM). In endothelial cells (EC) isolated from bone marrow (BM) MM patients (MMEC) reduces VEGFR2 cMet phosphorylation affects their downstream signaling cascades. influences secretory profile MMEC inhibits vitro angiogenic activities (spontaneous chemotactic migration,...
Interactions of multiple myeloma (MM) cells with endothelial (ECs) enhance angiogenesis and MM progression. Here, we investigated the role Notch signaling in cross talk between ECs enabling angiogenesis. MMECs showed higher expression Jagged1/2 ligands, activated Notch1/2 receptors, Hes1/Hey1 target genes than from monoclonal gammopathy undetermined significance patients, suggesting that homotypic activation pathway occurs MM. co-cultured triggered these through a cell-to-cell...
Multiple myeloma (MM) is a genetically heterogenous disease that includes subgroup of 10-15% patients facing dismal survival despite most intensive treatment. The aim this review article to provide an integrated clinical and biological overview on the high-risk MM discussing novel therapeutic perspectives aimed target neoplastic clone its microenvironment. dissection molecular determinants aggressive phenotypes drug resistance can foster better tailored management profile refractoriness...